Caxton Associates LLP Sells 259,388 Shares of 10x Genomics $TXG

Caxton Associates LLP lessened its position in 10x Genomics (NASDAQ:TXG) by 74.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 87,406 shares of the company’s stock after selling 259,388 shares during the period. Caxton Associates LLP owned about 0.07% of 10x Genomics worth $1,012,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in TXG. Allworth Financial LP raised its holdings in 10x Genomics by 150.4% in the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after acquiring an additional 1,364 shares during the last quarter. True Wealth Design LLC raised its stake in shares of 10x Genomics by 1,552.5% in the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after purchasing an additional 3,369 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of 10x Genomics by 153.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock valued at $45,000 after purchasing an additional 3,119 shares in the last quarter. US Bancorp DE boosted its position in shares of 10x Genomics by 314.5% during the first quarter. US Bancorp DE now owns 5,973 shares of the company’s stock valued at $52,000 after buying an additional 4,532 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in 10x Genomics by 48.1% in the 2nd quarter. Blue Trust Inc. now owns 4,894 shares of the company’s stock worth $57,000 after buying an additional 1,590 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on TXG. UBS Group upped their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. increased their price objective on shares of 10x Genomics from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Canaccord Genuity Group lifted their target price on shares of 10x Genomics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Finally, Barclays raised their price target on 10x Genomics from $17.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $15.73.

Insider Transactions at 10x Genomics

In other news, CFO Adam Taich sold 11,888 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $225,872.00. Following the completion of the transaction, the chief financial officer owned 297,385 shares of the company’s stock, valued at $5,650,315. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 8,283 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $157,377.00. Following the completion of the transaction, the insider directly owned 432,605 shares in the company, valued at approximately $8,219,495. This represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,432 shares of company stock valued at $635,208 over the last 90 days. Company insiders own 10.03% of the company’s stock.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $15.76 on Tuesday. The firm has a fifty day moving average price of $15.13 and a 200-day moving average price of $13.37. The stock has a market cap of $1.99 billion, a PE ratio of -25.42 and a beta of 2.14. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $20.34.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company had revenue of $149.00 million for the quarter, compared to analysts’ expectations of $142.50 million. During the same quarter in the previous year, the company earned ($0.30) EPS. 10x Genomics’s revenue for the quarter was down 1.7% on a year-over-year basis. On average, research analysts expect that 10x Genomics will post -1.43 EPS for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.